Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase

Stacey L. House, Brian E. House, Betty Glascock, Thomas Kimball, Eyad Nusayr, Jo El J Schultz, Thomas C Doetschman

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Fibroblast growth factor 2 (basic FGF or FGF2) has been shown to affect growth and differentiation in some tissues and to be required for cardiac hypertrophy in vivo. FGF2 has been shown in vitro to signal through the mitogen-activated protein kinase (MAPK) to affect cell survival and growth. To ascertain the role of FGF2 in cardiac hypertrophy, wildtype, Fgf2 knockout, non-transgenic, and FGF2 transgenic mice were treated with isoproterenol or saline via subcutaneous mini-osmotic pump implants to induce a hypertrophic response to β-adrenergic stimulation. Fgf2 knockout hearts are protected from isoproterenol-induced cardiac hypertrophy; whereas, FGF2 transgenic hearts show exacerbated cardiac hypertrophy as assessed by heart weight-to-body weight ratios and myocyte cross-sectional area. Echocardiography reveals significantly decreased fractional shortening in isoproterenol-treated FGF2 transgenic mice but not in Fgf2 knockout mice suggesting that FGF2 mediates the maladaptive cardiac dysfunction seen in cardiac hypertrophy induced by isoproterenol. Western blot analysis also reveals alterations in MAPK signaling in Fgf2 knockout and FGF2 transgenic hearts subjected to isoproterenol treatment, suggesting that this cascade mediates FGF2's pro-hypertrophic effect. Pharmacologic inhibition of extracellular signal-regulated kinase (ERK) signaling results in an attenuated hypertrophic response in isoproterenol-treated FGF2 transgenic mice, but this response is not seen with p38 mitogen-activated protein kinase (p38) pathway inhibition, suggesting that FGF2 activation of ERK but not p38 is necessary for FGF2's role in the mediation of cardiac hypertrophy.

Original languageEnglish (US)
Pages (from-to)143-154
Number of pages12
JournalMolecular and Cellular Pharmacology
Volume2
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Cardiomegaly
Fibroblast Growth Factor 2
Isoproterenol
Phosphotransferases
Transgenic Mice
Extracellular Signal-Regulated MAP Kinases
p38 Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinases
Growth
Knockout Mice
Adrenergic Agents
Muscle Cells
Echocardiography
Cell Survival
Western Blotting
Body Weight

Keywords

  • Basic FGF
  • Cardiac hypertrophy
  • ERK
  • Extracellular regulated kinase
  • FGF2
  • Fibroblast growth factor
  • Isoproterenol
  • MAPK
  • Mitogen associated protein kinase

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Biology

Cite this

Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase. / House, Stacey L.; House, Brian E.; Glascock, Betty; Kimball, Thomas; Nusayr, Eyad; Schultz, Jo El J; Doetschman, Thomas C.

In: Molecular and Cellular Pharmacology, Vol. 2, No. 4, 2010, p. 143-154.

Research output: Contribution to journalArticle

House, Stacey L. ; House, Brian E. ; Glascock, Betty ; Kimball, Thomas ; Nusayr, Eyad ; Schultz, Jo El J ; Doetschman, Thomas C. / Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase. In: Molecular and Cellular Pharmacology. 2010 ; Vol. 2, No. 4. pp. 143-154.
@article{4e5040dd312e42d1b7bb7f3bb809226e,
title = "Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase",
abstract = "Fibroblast growth factor 2 (basic FGF or FGF2) has been shown to affect growth and differentiation in some tissues and to be required for cardiac hypertrophy in vivo. FGF2 has been shown in vitro to signal through the mitogen-activated protein kinase (MAPK) to affect cell survival and growth. To ascertain the role of FGF2 in cardiac hypertrophy, wildtype, Fgf2 knockout, non-transgenic, and FGF2 transgenic mice were treated with isoproterenol or saline via subcutaneous mini-osmotic pump implants to induce a hypertrophic response to β-adrenergic stimulation. Fgf2 knockout hearts are protected from isoproterenol-induced cardiac hypertrophy; whereas, FGF2 transgenic hearts show exacerbated cardiac hypertrophy as assessed by heart weight-to-body weight ratios and myocyte cross-sectional area. Echocardiography reveals significantly decreased fractional shortening in isoproterenol-treated FGF2 transgenic mice but not in Fgf2 knockout mice suggesting that FGF2 mediates the maladaptive cardiac dysfunction seen in cardiac hypertrophy induced by isoproterenol. Western blot analysis also reveals alterations in MAPK signaling in Fgf2 knockout and FGF2 transgenic hearts subjected to isoproterenol treatment, suggesting that this cascade mediates FGF2's pro-hypertrophic effect. Pharmacologic inhibition of extracellular signal-regulated kinase (ERK) signaling results in an attenuated hypertrophic response in isoproterenol-treated FGF2 transgenic mice, but this response is not seen with p38 mitogen-activated protein kinase (p38) pathway inhibition, suggesting that FGF2 activation of ERK but not p38 is necessary for FGF2's role in the mediation of cardiac hypertrophy.",
keywords = "Basic FGF, Cardiac hypertrophy, ERK, Extracellular regulated kinase, FGF2, Fibroblast growth factor, Isoproterenol, MAPK, Mitogen associated protein kinase",
author = "House, {Stacey L.} and House, {Brian E.} and Betty Glascock and Thomas Kimball and Eyad Nusayr and Schultz, {Jo El J} and Doetschman, {Thomas C}",
year = "2010",
doi = "10.4255/mcpharmacol.10.20",
language = "English (US)",
volume = "2",
pages = "143--154",
journal = "Molecular and Cellular Pharmacology",
issn = "1938-1247",
publisher = "Lumitext Publishing",
number = "4",

}

TY - JOUR

T1 - Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase

AU - House, Stacey L.

AU - House, Brian E.

AU - Glascock, Betty

AU - Kimball, Thomas

AU - Nusayr, Eyad

AU - Schultz, Jo El J

AU - Doetschman, Thomas C

PY - 2010

Y1 - 2010

N2 - Fibroblast growth factor 2 (basic FGF or FGF2) has been shown to affect growth and differentiation in some tissues and to be required for cardiac hypertrophy in vivo. FGF2 has been shown in vitro to signal through the mitogen-activated protein kinase (MAPK) to affect cell survival and growth. To ascertain the role of FGF2 in cardiac hypertrophy, wildtype, Fgf2 knockout, non-transgenic, and FGF2 transgenic mice were treated with isoproterenol or saline via subcutaneous mini-osmotic pump implants to induce a hypertrophic response to β-adrenergic stimulation. Fgf2 knockout hearts are protected from isoproterenol-induced cardiac hypertrophy; whereas, FGF2 transgenic hearts show exacerbated cardiac hypertrophy as assessed by heart weight-to-body weight ratios and myocyte cross-sectional area. Echocardiography reveals significantly decreased fractional shortening in isoproterenol-treated FGF2 transgenic mice but not in Fgf2 knockout mice suggesting that FGF2 mediates the maladaptive cardiac dysfunction seen in cardiac hypertrophy induced by isoproterenol. Western blot analysis also reveals alterations in MAPK signaling in Fgf2 knockout and FGF2 transgenic hearts subjected to isoproterenol treatment, suggesting that this cascade mediates FGF2's pro-hypertrophic effect. Pharmacologic inhibition of extracellular signal-regulated kinase (ERK) signaling results in an attenuated hypertrophic response in isoproterenol-treated FGF2 transgenic mice, but this response is not seen with p38 mitogen-activated protein kinase (p38) pathway inhibition, suggesting that FGF2 activation of ERK but not p38 is necessary for FGF2's role in the mediation of cardiac hypertrophy.

AB - Fibroblast growth factor 2 (basic FGF or FGF2) has been shown to affect growth and differentiation in some tissues and to be required for cardiac hypertrophy in vivo. FGF2 has been shown in vitro to signal through the mitogen-activated protein kinase (MAPK) to affect cell survival and growth. To ascertain the role of FGF2 in cardiac hypertrophy, wildtype, Fgf2 knockout, non-transgenic, and FGF2 transgenic mice were treated with isoproterenol or saline via subcutaneous mini-osmotic pump implants to induce a hypertrophic response to β-adrenergic stimulation. Fgf2 knockout hearts are protected from isoproterenol-induced cardiac hypertrophy; whereas, FGF2 transgenic hearts show exacerbated cardiac hypertrophy as assessed by heart weight-to-body weight ratios and myocyte cross-sectional area. Echocardiography reveals significantly decreased fractional shortening in isoproterenol-treated FGF2 transgenic mice but not in Fgf2 knockout mice suggesting that FGF2 mediates the maladaptive cardiac dysfunction seen in cardiac hypertrophy induced by isoproterenol. Western blot analysis also reveals alterations in MAPK signaling in Fgf2 knockout and FGF2 transgenic hearts subjected to isoproterenol treatment, suggesting that this cascade mediates FGF2's pro-hypertrophic effect. Pharmacologic inhibition of extracellular signal-regulated kinase (ERK) signaling results in an attenuated hypertrophic response in isoproterenol-treated FGF2 transgenic mice, but this response is not seen with p38 mitogen-activated protein kinase (p38) pathway inhibition, suggesting that FGF2 activation of ERK but not p38 is necessary for FGF2's role in the mediation of cardiac hypertrophy.

KW - Basic FGF

KW - Cardiac hypertrophy

KW - ERK

KW - Extracellular regulated kinase

KW - FGF2

KW - Fibroblast growth factor

KW - Isoproterenol

KW - MAPK

KW - Mitogen associated protein kinase

UR - http://www.scopus.com/inward/record.url?scp=78049438071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049438071&partnerID=8YFLogxK

U2 - 10.4255/mcpharmacol.10.20

DO - 10.4255/mcpharmacol.10.20

M3 - Article

VL - 2

SP - 143

EP - 154

JO - Molecular and Cellular Pharmacology

JF - Molecular and Cellular Pharmacology

SN - 1938-1247

IS - 4

ER -